LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Protein Score from Single Plasma Sample Predicts Cardiovascular Disease

By LabMedica International staff writers
Posted on 23 Aug 2023
Image: Researchers used AI to develop a protein score to predict major atherosclerotic cardiovascular disease events (Photo courtesy of Freepik)
Image: Researchers used AI to develop a protein score to predict major atherosclerotic cardiovascular disease events (Photo courtesy of Freepik)

In a large retrospective analysis, utilizing measurements of plasma proteins from thousands of individuals across primary and secondary event populations, researchers have harnessed artificial intelligence (AI) to create a protein score for predicting major atherosclerotic cardiovascular disease events (ASCVD).

The study by scientists from deCODE genetics (Reykjavik, Iceland) was based on an extensive dataset comprising more than 13,500 Icelanders without a history of major ASCVD prior to plasma sampling, as well as over 6,000 participants from the FOURIER trial who had already experienced ASCVD before plasma sampling. In all these cases, plasma protein levels were assessed using the SomaScan platform, measuring approximately 5,000 plasma proteins. Notably, the protein risk score, derived solely from proteomics data of a single plasma sample, effectively predicts ASCVD events even without access to medical history or risk factor information. While much of the risk assessed by the proteins is also reflected in established risk factors, the protein score captures additional risk.

Furthermore, the protein risk score is a dynamic measure. Unlike certain immutable classic risk factors like family history and prior ASCVD events, this score can be modified upon treatment. The dynamic nature of protein risk scores—where protein levels fluctuate in relation to the timing of events—makes them well-suited for predicting event timelines. Consequently, these protein risk scores could prove invaluable in clinical trials for early evaluation of treatment efficacy or risk monitoring.

“We believe that in the proteomic risk score, we may have a biomarker that will allow the world to conduct shorter clinical trials with fewer participants,” said Kari Stefansson, CEO of deCODE genetics and one of the senior investigators of the study. “This is going to make the development of new medicines less expensive and make them available sooner for those who need them. Furthermore, in clinical practice it may allow for more effective prevention of ASCVD.”

Related Links:
deCODE genetics 

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more